The objective of a new study published in Expert Review of Vaccines was to test whether the integration of hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliovirus, Haemophilus influenzae type b conjugate (DTPa-HBV-IPV/Hib) vaccine within existing national recommendations in the Asia Pacific region could replace vaccines included in the primary vaccination series, with the aim of reducing the number of injections during infancy. This study entailed a search for clinical trials conducted in South-East Asia and Western Pacific Regions that investigated vaccination regimens with >3 doses of HBV-containing vaccines in infants, including a monovalent HBV vaccine birth dose and ≥1 dose of hexavalent DTPa-HBV-IPV/Hib vaccine. Six clinical trials were selected for the review. The findings showed that infants who received monovalent HBV vaccine at birth and 3 or 4 doses of DTPa-HBV-IPV/Hib vaccine achieved protective immunogenic titers with a clinically acceptable safety profile. The results indicated that the integration of hexavalent DTPa-HBV-IPV/Hib vaccine within existing national recommendations in the Asia Pacific region could be implemented to reduce the number of injections during infancy.